Holen Sie sich die Stockscreener-App
5.54
3.35%
-0.13
Schlusskurs vom Vortag:
$5.67
Offen:
$5.77
24-Stunden-Volumen:
209.82K
Relative Volume:
0.91
Marktkapitalisierung:
$132.88M
Einnahmen:
$34.26M
Nettoeinkommen (Verlust:
$-46.61M
KGV:
-1.079
EPS:
-5.1345
Netto-Cashflow:
$-76.16M
1W Leistung:
+18.87%
1M Leistung:
+40.87%
6M Leistung:
+18.87%
1J Leistung:
+8.51%
1-Tages-Spanne:
$5.40
$6.05
1-Wochen-Bereich:
$4.48
$6.05
52-Wochen-Spanne:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
5.52 | 136.49M | 34.26M | -46.61M | -76.16M | -5.1345 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.43 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.46 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
702.12 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.58 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
283.80 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet
Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - pharmiweb.com
Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria
Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus
Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView
Precision BioSciences: Q4 Earnings Snapshot - Bluefield Daily Telegraph
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Yahoo! Finance Canada
Precision BioSciences (DTIL) Secures Key Patent Allowances for P - GuruFocus
Precision BioSciences receives patent allowances for hepatitis B program - Investing.com Australia
Precision BioSciences receives patent allowances for hepatitis B program By Investing.com - Investing.com Nigeria
Precision BioSciences, Inc. Receives U.S. Patent Allowances Covering PBGENE-HBV Program - marketscreener.com
Precision BioSciences receives U.S. patent allowances covering the PBGENE-HBV program - marketscreener.com
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - TradingView
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - BioSpace
Precision BioSciences Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Precision BioSciences (DTIL) Presents Promising Preclinical Data for DMD Therapy - GuruFocus
Precision BioSciences presents preclinical data on DMD therapy - Investing.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - BioSpace
Precision BioSciences to Report Q4 and Fiscal Year 2025 Results - National Today
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - BioSpace
Precision BioSciences Says PBGENE-DMD Receives FDA Fast Track Designation - marketscreener.com
Precision BioSciences stock jumps on FDA Fast Track status By Investing.com - Investing.com Canada
FDA Grants Fast Track Status to Precision BioSciences' (DTIL) PB - GuruFocus
Earnings Beat: Is Precision BioSciences Inc stock trending bullishPortfolio Update Summary & Real-Time Volume Triggers - baoquankhu1.vn
Market Outlook: Is Precision BioSciences Inc. stock a smart buy before Fed meeting2025 Investor Takeaways & Fast Gain Swing Alerts - Naître et grandir
Guidance Update: What is the long term forecast for Precision BioSciences Inc stockWeekly Trade Analysis & Verified Short-Term Trading Plans - baoquankhu1.vn
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Intellectia AI
Risk Off: Whats the outlook for Precision BioSciences Incs sectorMarket Growth Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Precision BioSciences: $7.5 Million Milestone From TG Therapeutics For Azer-Cel Clinical Progress In Multiple Sclerosis - Pulse 2.0
Forecast Cut: What is the long term forecast for Precision BioSciences Inc stockInsider Selling & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - 01net
Aug Macro: How does Precision BioSciences Inc compare to its peers2025 Price Momentum & Real-Time Volume Analysis - baoquankhu1.vn
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch? - AD HOC NEWS
Stock Analysis: How does Precision BioSciences Inc compare to its peersInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
DTIL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Block Trades: Is Precision BioSciences Inc a speculative investmentBear Alert & Expert Approved Trade Ideas - baoquankhu1.vn
Precision BioSciences (DTIL) Price Target Decreased by 10.55% to 33.15 - MSN
What’s the outlook for Precision BioSciences Inc.’s sector2025 Bull vs Bear & Expert Curated Trade Setups - mfd.ru
Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares - MarketBeat
John Alexander Kelly Sells 8,149 Shares of Precision BioSciences (NASDAQ:DTIL) Stock - MarketBeat
Precision Biosciences (DTIL) CFO logs RSU vesting and tax sell-to-cover - Stock Titan
Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in Stock - MarketBeat
DTIL (NASDAQ: DTIL) trustee sold 10,200 shares; 4,925 vesting reported - Stock Titan
FDA Clears ARCUS Editor for Duchenne Hot-spot - CRISPR Medicine News
Top 15 Female Motivational Speakers in the UK Revealed in 2026 Shortlist - Weekly Voice
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):